Price$5.49-8.44 (-60.59%)
2025-09-102025-12-11
Latest news
25 items- SECSEC Form S-8 filed by Predictive Oncology Inc.S-8 - Axe Compute Inc. (0001446159) (Filer)
- SECPredictive Oncology Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Axe Compute Inc. (0001446159) (Filer)
- INSIDERChief Executive Officer Vennare Raymond F covered exercise/tax liability with 2,373 shares, decreasing direct ownership by 27% to 6,418 units (SEC Form 4)4 - Predictive Oncology Inc. (0001446159) (Issuer)
- SECPredictive Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Predictive Oncology Inc. (0001446159) (Filer)
- PRPredictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementPITTSBURGH, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today announced that on December 1, 2025, the Company received a notification letter from Nasdaq notifying the Company that it regained compliance with Nasdaq's minimum stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000. As a result, the Company's shares will continue to trade on the Nasdaq Capital Market under the ticker "POAI."
- SECSEC Form EFFECT filed by Predictive Oncology Inc.EFFECT - Predictive Oncology Inc. (0001446159) (Filer)
- SECPredictive Oncology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Predictive Oncology Inc. (0001446159) (Filer)
- SECSEC Form 424B3 filed by Predictive Oncology Inc.424B3 - Predictive Oncology Inc. (0001446159) (Filer)
- SECSEC Form 424B3 filed by Predictive Oncology Inc.424B3 - Predictive Oncology Inc. (0001446159) (Filer)
- SECPredictive Oncology Inc. filed SEC Form 8-K: Other Events8-K - Predictive Oncology Inc. (0001446159) (Filer)
- SECAmendment: SEC Form S-3/A filed by Predictive Oncology Inc.S-3/A - Predictive Oncology Inc. (0001446159) (Filer)
- SECPredictive Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Predictive Oncology Inc. (0001446159) (Filer)
- SECPredictive Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Predictive Oncology Inc. (0001446159) (Filer)
- SECSEC Form 10-Q filed by Predictive Oncology Inc.10-Q - Predictive Oncology Inc. (0001446159) (Filer)
- PRPredictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset StrategyPITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlights: Announced the initiation of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem, supported by two private placements pursuant to which the Company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of lo
- SECPredictive Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Predictive Oncology Inc. (0001446159) (Filer)
- SECSEC Form 424B5 filed by Predictive Oncology Inc.424B5 - Predictive Oncology Inc. (0001446159) (Filer)
- SECSEC Form DEF 14A filed by Predictive Oncology Inc.DEF 14A - Predictive Oncology Inc. (0001446159) (Filer)
- SECSEC Form S-3 filed by Predictive Oncology Inc.S-3 - Predictive Oncology Inc. (0001446159) (Filer)
- SECSEC Form S-3 filed by Predictive Oncology Inc.S-3 - Predictive Oncology Inc. (0001446159) (Filer)
- SECSEC Form D filed by Predictive Oncology Inc.D - Predictive Oncology Inc. (0001446159) (Filer)
- SECSEC Form D filed by Predictive Oncology Inc.D - Predictive Oncology Inc. (0001446159) (Filer)
- INSIDERSEC Form 3 filed by new insider Matthews Shawn3 - Predictive Oncology Inc. (0001446159) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mclaughlin Thomas Louis3 - Predictive Oncology Inc. (0001446159) (Issuer)
- SECPredictive Oncology Inc. filed SEC Form 8-K: Shareholder Director Nominations8-K - Predictive Oncology Inc. (0001446159) (Filer)
POAI FAQ
6 questionsWhat does Predictive Oncology Inc. do?
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during...Where does POAI stock trade?
Predictive Oncology Inc. (POAI) is listed on NASDAQ.What sector and industry is POAI in?
Predictive Oncology Inc. operates in the Health Care sector, Industrial Specialties industry.What are analysts saying about POAI?
Predictive Oncology Inc. has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $300.00 price target on 2024-08-19. Recent price targets range from $300.00 to $500.00.What companies are similar to POAI?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare POAI side-by-side with any of them on Quantisnow.How can I track POAI on Quantisnow?
Quantisnow aggregates Predictive Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow POAI to receive live email and push alerts on every new disclosure.